Evidence map›Paper›PMID 32914194›Full record

ArticleJournal of Crohn's & colitis2021

Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint.

Sushrut Jangi, Ariela K Holmer, Parambir S Dulai, Brigid S Boland, Angelina E Collins, Lysianne Pham, William J Sandborn, Siddharth Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Diagnosis and Monitoring of Ulcerative Colitis.Clinics in colon and rectal surgery · 2022
    Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sushrut JangiDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Ariela K HolmerDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Parambir S DulaiDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Brigid S BolandDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Angelina E CollinsDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Lysianne PhamDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
William J SandbornDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Siddharth SinghDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.

Funding

San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN · 2019 to 2026
$10.8M
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
NIDDK NIH HHS K23 DK117058NIDDK NIH HHS P30 DK120515
6 · The paper itself

Abstract

backgroundDeep remission in patients with UC has relied on initial achievement of biochemical, endoscopic, and/or histological remission. We evaluated persistent symptomatic remission and endoscopic healing (EH: Mayo endoscopy score [MES] 0 or 1) on consecutive endoscopic examinations as a durable treatment endpoint.

methodsIn a retrospective cohort study, we estimated and compared cumulative risk of clinical relapse in patients with persistent EH, with and without persistent histological remission and depth of EH, among adults with active UC treated-to-target of symptomatic remission and EH who achieved and maintained symptomatic remission and EH over two serial endoscopic assessments. We also explored risk of relapse in patients with persistent EH whose therapy was de-escalated.

resultsOf 270 patients who initially achieved EH with treatment-to-target, 89 maintained symptomatic remission and EH on follow-up endoscopy [interval between EH1 and EH2, 16 months]. On follow-up after EH2 [median, 19 months], 1-year cumulative risk of relapse in patients with persistent EH was 11.5%, and with persistent histological remission was 9.5%. Seventeen patients with persistent EH, who underwent de-escalation of therapy, did not have an increased risk of relapse as compared with patients who continued index therapy [5.3% vs 14%, p = 0.16].

conclusionsPatients with active UC treated-to-target of clinical remission, who achieve and maintain symptomatic remission and EH over consecutive endoscopies, have a low risk of relapse, particularly in a subset of patients who simultaneously achieve histological remission. Persistent EH should be examined as a treatment endpoint suggestive of deep remission.

Indexed as

ColonoscopyBiopsyColitis, UlcerativeEndpoint DeterminationFemaleHumansMaleMiddle AgedRecurrenceRemission InductionRetrospective StudiesRiskWound Healingbiologicsdeep remissionflareInflammatory bowel diseases

Identifiers

PMID32914194
PMCPMC8023862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.